PDS Biotechnology sets 2026 annual meeting, proposal deadline
PDS Biotechnology Corporation has scheduled its 2026 Annual Meeting of Stockholders for August 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
PDS Biotechnology Corporation has scheduled its 2026 Annual Meeting of Stockholders for August 10, 2026. The meeting date is more than 30 days after the anniversary of the 2025 Annual Meeting, so the company has set a special deadline for stockholder proposals.
Stockholders seeking to include proposals in the proxy materials under SEC Rule 14a-8 must submit them by June 25, 2026. Eligible proposals must comply with SEC rules and should be sent to the Corporate Secretary at the company’s Princeton, New Jersey headquarters.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
2026 annual meeting date: August 10, 2026
Proposal deadline: June 25, 2026
Company address: 303A College Road East, Princeton, NJ 08540
+1 more
4 metrics
2026 annual meeting date
August 10, 2026
Scheduled date for 2026 Annual Meeting of Stockholders
Proposal deadline
June 25, 2026
Cutoff for Rule 14a-8 stockholder proposals for proxy inclusion
Company address
303A College Road East, Princeton, NJ 08540
Location for submitting stockholder proposals
Company phone
(800) 208-3343
Registrant’s telephone number
Key Terms
Annual Meeting of Stockholders, Definitive Proxy Statement, Rule 14a-8, proxy materials, +1 more
5 terms
Annual Meeting of Stockholders financial
"The Board has scheduled the Company’s 2026 Annual Meeting of Stockholders for August 10, 2026."
Definitive Proxy Statement regulatory
"More detailed information will be set forth in the Company’s Definitive Proxy Statement on Schedule 14A."
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
Rule 14a-8 regulatory
"Deadline of June 25, 2026 for the submission of stockholder proposals pursuant to Rule 14a-8 of the Exchange Act."
Rule 14a-8 is a U.S. Securities and Exchange Commission regulation that lets eligible shareholders put proposals on a public company’s proxy ballot for an annual meeting, provided they meet basic ownership and filing requirements. It matters to investors because it creates a formal way to raise governance or strategic issues and force a company-wide vote—like getting an item onto the agenda of a neighborhood association meeting once you’ve lived there long enough—so shareholders can push for change or influence management decisions.
proxy materials financial
"Proposals for inclusion in the Company’s proxy materials for the 2026 Annual Meeting."
Proxy materials are the packet of documents sent to shareholders that explain items to be voted on at a company meeting and include the actual ballot or instructions for casting a vote. Think of them as a voting packet that lays out who’s running the company, major proposals (like pay, mergers, or board changes), and arguments for and against each item. Investors care because those votes shape corporate direction, affect risk and future profits, and can influence share value.
Emerging growth company regulatory
"Emerging growth company Yes No"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When is PDSB's 2026 Annual Meeting of Stockholders scheduled?
PDS Biotechnology’s 2026 Annual Meeting of Stockholders is scheduled for August 10, 2026. This later-than-usual date triggers special timing rules for shareholder proposals under SEC regulations and will be detailed further in the company’s upcoming definitive proxy statement.
What is the deadline for PDSB stockholder proposals for the 2026 Annual Meeting?
The deadline for PDS Biotechnology stockholder proposals under SEC Rule 14a-8 is June 25, 2026. Proposals received by this date may be eligible for inclusion in the company’s 2026 proxy materials if they fully comply with applicable SEC rules and company requirements.
Why did PDSB set a special proposal deadline for the 2026 Annual Meeting?
PDS Biotechnology set a June 25, 2026 proposal deadline because the 2026 Annual Meeting will occur more than 30 days after the anniversary of the 2025 meeting. SEC rules allow companies to adjust Rule 14a-8 deadlines when annual meeting timing shifts significantly year over year.
Where should PDSB stockholders send Rule 14a-8 proposals for 2026?
Stockholder proposals for PDS Biotechnology’s 2026 Annual Meeting should be mailed to PDS Biotechnology Corporation, 303A College Road East, Princeton, New Jersey 08540, Attention: Corporate Secretary. Proposals must arrive by June 25, 2026 and comply with all SEC Rule 14a-8 requirements.
Will PDSB automatically include all timely proposals in its 2026 proxy?
No. PDS Biotechnology may omit proposals that do not comply with SEC Rule 14a-8. Even if submitted by June 25, 2026, proposals must meet all substantive and procedural requirements for inclusion in the company’s definitive proxy statement for the 2026 Annual Meeting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates